Phc5 Choice of Hemostatic Agent and Hospital Length of Stay in Cardiovascular Surgery

Krishnan, Sindhu; Conner, TM; Leslie, RC; Stemkowski, Stephen

doi:10.1016/s1098-3015(10)73373-8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, two gelatin matrix hemostatic sealants, Floseal (Baxter Healthcare Corporation Fremont, CA94555, USA) and Surgi o (Ethicon Endo-Surgery, part of Johnson & Johnson Company, New Jersey 08876, USA) have been approved by the United States Food and Drug Administration for clinical use [10] . Preparation methods of Surgi o and Floseal are similar, which have been widely utilized in cardiac surgery [11,12] , sinus surgery [13][14][15][16] , urologic surgery [17][18][19] , etc. And, by now there are dozens of clinical research to explore the e cacy and safety of two typical thrombin-based owable hemostatic agents(Floseal and Surgi o) in spine surgery [20][21][22][23][24][25] .…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of thrombin-based flowable hemostatic agents in spine surgery: a protocol for systematic review and meta- analysis

YangMasood

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction As hemostasis is a complex process that bleeding can be difficult to control, higher requirements are needed for spinal surgeons in intraoperative hemostasis. Floseal and Surgiflo are two common thrombin-based flowable hemostatic agents. Nevertheless, Floseal or Surgiflo has not been universally recommended by the current guidelines of preoperative hemostatic management in spine surgery due to lack of relative systematic evidence-based medical evidence. Moreover, adverse effects of novel absorbable hemostatic biomaterial may be poorly reported and inconsistently described. Meanwhile, there is currently no systematic review and meta-analyses available which sum up the existing evidence. Our study aims to explore the efficacy and safety of thrombin-based flowable hemostatic agents in spine surgery, and to provide corresponding evidence-based medical evidence. Methods and analysis Our study will conduct a systematic review and meta-analysis to explore the efficacy and safety of thrombin-based flowable hemostatic agents in spine surgery, based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P). Two authors will retrieve the relevant articles using the eight databases (PubMed, Scopus, Embase, Cochrane Library, Web of Science, CNKI, Wanfang and CBM) from inception to 16st Aug, 2022. Three authors will screen citation titles and abstracts and evaluated full-text of each potentially relevant citation, and then extract the data using a data extraction form. Any discrepancies in decisions between reviewers will be resolved through discussion. All included studies will be evaluated for quality and risk of bias according to the Cochrane guidelines. A subgroup analysis and a sensitivity analysis will be used to find the main source of between-study heterogeneity. All data analysis will be performed using RevMan v.5.3 Software provided by the Cochrane Collaboration.

show abstract